Effective **January 1, 2020**, new guidance has been provided for the use of non-culture based testing methodologies (NCT) as it relates to laboratory-confirmed bloodstream infections (LCBI).

If blood is collected for culture within **2 days before, or 1 day after** the NCT, disregard the result of the NCT and use **ONLY** the result of the culture to make an LCBI surveillance determination. If no blood is collected for culture within this time period, use the result of the NCT for LCBI surveillance determination.¹

**New CDC/NHSN Guidance Related to T2 Biosystems Testing and CLABSI Impact**

"The T2Bacteria Test Panel represents a **substantial clinical improvement over existing technologies** because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections."²

²The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections."²
Species identification in just hours

Data generated by T2Bacteria users demonstrate its ability to benefit patients in the emergency department by providing information that leads to more rapid time to delivery of effective therapy, de-escalation of unnecessary therapy, and helping avoid premature discharge and readmission to the emergency department.1

With T2Candida, multiple hospitals have shown that making targeted treatment decisions faster leads to improved outcomes, better stewardship, and reduces the cost of sepsis management. These institutions have independently reported significant reductions in length of stay and antifungal utilization, as well as substantial cost savings.2,3

*A combination of samples was run in both the prospective and contrived arms of the study. T2Bacteria showed an overall average sensitivity of 90% in the prospective arm of the study, with an overall average PPA of 97% in the contrived arm of the study.

Visit www.t2biosystems.com to learn more